Caricamento...
Natalizumab: Perspectives from the Bench to Bedside
Probably no other disease-modifying drug for multiple sclerosis has a more fascinating story than natalizumab from both the bench to bedside perspective and the postmarketing experience standpoint. Natalizumab is a monoclonal antibody that inhibits the trafficking of lymphocytes from the blood into...
Salvato in:
| Pubblicato in: | Cold Spring Harb Perspect Med |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Cold Spring Harbor Laboratory Press
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280713/ https://ncbi.nlm.nih.gov/pubmed/29500304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/cshperspect.a029066 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|